A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

• Status: Active, not recruiting
• Trial end date: 2024-10-25
• Target enrollment: 0
• Participant gender: All

Summary

A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Documented IDH1R132-mutant tumors

• ECOG performance status ≤ 2

Exclusion Criteria:

• Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients)

• Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease.

• Acute Promyelocytic Leukemia

• Women who are pregnant or lactating

Other protocol-defined Inclusion/Exclusion may apply